OS Therapies Plans Conditional Marketing Authorization Applications by Q1 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy OSTX?
Source: Benzinga
- Market Authorization Progress: OS Therapies expects to submit conditional Marketing Authorization Applications to the UK’s MHRA and the European EMA by Q1 2026, indicating significant progress in its drug approval process that could lay the groundwork for future revenue growth.
- FDA Clinical Module Submission: The company plans to submit the Clinical BLA module to the FDA following a Type D meeting anticipated in March 2026, which could expedite product approval and enhance its competitive position in the market if successful.
- Biomarker Data Release: OS Therapies is set to release additional biomarker data from its Human Metastatic Osteosarcoma Program in Q1 2026, aiming to evaluate the relationship between biomarker expression and clinical outcomes, potentially providing surrogate endpoints for clinical efficacy and improving treatment effectiveness.
- Stock Performance Analysis: Currently trading at $1.25, OS Therapies' stock is 8.0% below its 20-day simple moving average, indicating short-term weakness; however, analysts maintain a “Buy” rating with a price target of $18.25, reflecting confidence in the company's long-term potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OSTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OSTX
Wall Street analysts forecast OSTX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.170
Low
6.00
Averages
11.50
High
17.00
Current: 1.170
Low
6.00
Averages
11.50
High
17.00
About OSTX
OS Therapies Incorporated is a clinical-stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma and other solid tumors. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OS Therapies Plans Conditional Marketing Authorization Applications by Q1 2026
- Market Authorization Progress: OS Therapies expects to submit conditional Marketing Authorization Applications to the UK’s MHRA and the European EMA by Q1 2026, indicating significant progress in its drug approval process that could lay the groundwork for future revenue growth.
- FDA Clinical Module Submission: The company plans to submit the Clinical BLA module to the FDA following a Type D meeting anticipated in March 2026, which could expedite product approval and enhance its competitive position in the market if successful.
- Biomarker Data Release: OS Therapies is set to release additional biomarker data from its Human Metastatic Osteosarcoma Program in Q1 2026, aiming to evaluate the relationship between biomarker expression and clinical outcomes, potentially providing surrogate endpoints for clinical efficacy and improving treatment effectiveness.
- Stock Performance Analysis: Currently trading at $1.25, OS Therapies' stock is 8.0% below its 20-day simple moving average, indicating short-term weakness; however, analysts maintain a “Buy” rating with a price target of $18.25, reflecting confidence in the company's long-term potential.
See More
OS Therapies (OSTX) Reports Positive OST-HER2 Data but Shares Drop 4.52%
- Clinical Trial Progress: OS Therapies' Phase 2b trial of OST-HER2 revealed that immune blood biomarkers in the interferon gamma pathway effectively distinguish long-term from short-term survivors, bolstering their Biologics License Application (BLA) submission.
- Regulatory Approval Path: The company plans to submit its BLA to the FDA by Q2 2026, with regulatory approvals anticipated in the UK, US, and Europe by the end of 2026, indicating strong potential for market entry.
- Poor Stock Performance: Despite positive clinical data, OSTX shares fell 4.52% to $1.48, trading 2.5% below the 20-day and 12.8% below the 50-day simple moving averages, reflecting market caution regarding future performance.
- Mixed Market Signals: The current RSI of 47.78 suggests neutral territory, while the MACD indicates a potential bullish signal, reflecting complex market sentiment towards OSTX, necessitating investor vigilance.
See More
Oncolytics Biotech Appoints New Executives to Accelerate Cancer Treatment Progress
- Market Potential: The global immuno-oncology market is projected to surge from $35 billion to $185.69 billion, reflecting strong demand for coordinated immune system activation, attracting capital influx and driving the precision medicine market to $537.17 billion.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will enhance the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks, with a median duration of response reaching 17 months, indicating potential for accelerated approval in a setting with no FDA-approved options.
- FDA Design Approval: Oncolytics secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its leadership in the oncology immunotherapy space.
See More
Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044
- IP Expansion: Oncolytics Biotech filed a Track 1 prioritized examination patent application with the USPTO in Q3 2025 for manufacturing innovations related to pelareorep, which, if granted, could extend its commercial protection to 2044, thereby enhancing its competitive market position.
- Significant Clinical Results: Pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than the 6-11% response rate for chemotherapy alone, potentially driving a $20 billion market growth.
- Expert Team Expansion: Oncolytics Biotech expanded its Gastrointestinal Tumor Scientific Advisory Board by adding three globally recognized experts from leading cancer centers, enhancing academic support for its clinical research and further elevating the company's reputation in the industry.
- Successful FDA Alignment: The company secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial planned for this disease in the market.
See More
OS Therapies Under Investigation for Potential Director Misconduct
- Investigation Launched: Purcell & Lefkowitz LLP is investigating OS Therapies Incorporated to determine whether the company's directors breached their fiduciary duties in recent corporate actions, which could impact shareholder rights.
- Shareholder Rights Focus: The investigation aims to protect the interests of OS Therapies shareholders, and those interested in more information can contact the law firm through provided channels to ensure their rights are upheld.
- Legal Support Commitment: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide against securities fraud and other corporate misconduct, demonstrating a strong commitment to safeguarding shareholder interests.
- Potential Impact: Should the investigation confirm director misconduct, it could lead to legal liabilities and shareholder lawsuits for the company, negatively affecting its stock price and market reputation.
See More
Stonegate Capital Partners Revises Coverage for OS Therapies Inc. (OSTX) in Q3 2025
Clinical Milestones: OS Therapies Inc. reported a 75% two-year overall survival (OS) rate for its OST-HER2 treatment in a Phase 2b trial, significantly outperforming historical controls at 40%.
Regulatory Progress: The company is on track for U.S. and U.K. regulatory filings, with submissions to the FDA and UK MHRA expected by early 2026, supported by positive trial results.
Spinoff Announcement: OS Therapies plans to spin off its OS Animal Health division into a standalone public company in the first half of 2026, allowing shareholders to receive direct equity in the new entity.
Financial Overview: The company ended the quarter with approximately $1.9 million in cash and a net loss of $6.9 million, but secured $7.8 million in warrant proceeds post-quarter, extending its financial runway into late 2026.
See More
OS Therapies Plans Conditional Marketing Authorization Applications by Q1 2026
- Market Authorization Progress: OS Therapies expects to submit conditional Marketing Authorization Applications to the UK’s MHRA and the European EMA by Q1 2026, indicating significant progress in its drug approval process that could lay the groundwork for future revenue growth.
- FDA Clinical Module Submission: The company plans to submit the Clinical BLA module to the FDA following a Type D meeting anticipated in March 2026, which could expedite product approval and enhance its competitive position in the market if successful.
- Biomarker Data Release: OS Therapies is set to release additional biomarker data from its Human Metastatic Osteosarcoma Program in Q1 2026, aiming to evaluate the relationship between biomarker expression and clinical outcomes, potentially providing surrogate endpoints for clinical efficacy and improving treatment effectiveness.
- Stock Performance Analysis: Currently trading at $1.25, OS Therapies' stock is 8.0% below its 20-day simple moving average, indicating short-term weakness; however, analysts maintain a “Buy” rating with a price target of $18.25, reflecting confidence in the company's long-term potential.
See More
OS Therapies (OSTX) Reports Positive OST-HER2 Data but Shares Drop 4.52%
- Clinical Trial Progress: OS Therapies' Phase 2b trial of OST-HER2 revealed that immune blood biomarkers in the interferon gamma pathway effectively distinguish long-term from short-term survivors, bolstering their Biologics License Application (BLA) submission.
- Regulatory Approval Path: The company plans to submit its BLA to the FDA by Q2 2026, with regulatory approvals anticipated in the UK, US, and Europe by the end of 2026, indicating strong potential for market entry.
- Poor Stock Performance: Despite positive clinical data, OSTX shares fell 4.52% to $1.48, trading 2.5% below the 20-day and 12.8% below the 50-day simple moving averages, reflecting market caution regarding future performance.
- Mixed Market Signals: The current RSI of 47.78 suggests neutral territory, while the MACD indicates a potential bullish signal, reflecting complex market sentiment towards OSTX, necessitating investor vigilance.
See More
Oncolytics Biotech Appoints New Executives to Accelerate Cancer Treatment Progress
- Market Potential: The global immuno-oncology market is projected to surge from $35 billion to $185.69 billion, reflecting strong demand for coordinated immune system activation, attracting capital influx and driving the precision medicine market to $537.17 billion.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will enhance the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks, with a median duration of response reaching 17 months, indicating potential for accelerated approval in a setting with no FDA-approved options.
- FDA Design Approval: Oncolytics secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its leadership in the oncology immunotherapy space.
See More
Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044
- IP Expansion: Oncolytics Biotech filed a Track 1 prioritized examination patent application with the USPTO in Q3 2025 for manufacturing innovations related to pelareorep, which, if granted, could extend its commercial protection to 2044, thereby enhancing its competitive market position.
- Significant Clinical Results: Pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than the 6-11% response rate for chemotherapy alone, potentially driving a $20 billion market growth.
- Expert Team Expansion: Oncolytics Biotech expanded its Gastrointestinal Tumor Scientific Advisory Board by adding three globally recognized experts from leading cancer centers, enhancing academic support for its clinical research and further elevating the company's reputation in the industry.
- Successful FDA Alignment: The company secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial planned for this disease in the market.
See More
OS Therapies Under Investigation for Potential Director Misconduct
- Investigation Launched: Purcell & Lefkowitz LLP is investigating OS Therapies Incorporated to determine whether the company's directors breached their fiduciary duties in recent corporate actions, which could impact shareholder rights.
- Shareholder Rights Focus: The investigation aims to protect the interests of OS Therapies shareholders, and those interested in more information can contact the law firm through provided channels to ensure their rights are upheld.
- Legal Support Commitment: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide against securities fraud and other corporate misconduct, demonstrating a strong commitment to safeguarding shareholder interests.
- Potential Impact: Should the investigation confirm director misconduct, it could lead to legal liabilities and shareholder lawsuits for the company, negatively affecting its stock price and market reputation.
See More
Stonegate Capital Partners Revises Coverage for OS Therapies Inc. (OSTX) in Q3 2025
Clinical Milestones: OS Therapies Inc. reported a 75% two-year overall survival (OS) rate for its OST-HER2 treatment in a Phase 2b trial, significantly outperforming historical controls at 40%.
Regulatory Progress: The company is on track for U.S. and U.K. regulatory filings, with submissions to the FDA and UK MHRA expected by early 2026, supported by positive trial results.
Spinoff Announcement: OS Therapies plans to spin off its OS Animal Health division into a standalone public company in the first half of 2026, allowing shareholders to receive direct equity in the new entity.
Financial Overview: The company ended the quarter with approximately $1.9 million in cash and a net loss of $6.9 million, but secured $7.8 million in warrant proceeds post-quarter, extending its financial runway into late 2026.
See More
